Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07425015 · ClinicalTrials.gov registry record · NA

Ambulatory Long Length URodynamics Evaluation

A NA study of Benign Prostatic Hyperplasia and Urinary Bladder, Overactive, sponsored by Bright Uro.

Recruiting
Registry status
NA
Development phase
101
Enrollment target
7
Study locations

NCT07425015 is a NA study of Benign Prostatic Hyperplasia and Urinary Bladder, Overactive that is actively recruiting participants, run by Bright Uro. The registered enrollment target is 101 participants, below the 549-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (82% lower). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07425015, a NA study of Benign Prostatic Hyperplasia and Urinary Bladder, Overactive, is actively recruiting participants, sponsored by Bright Uro.

RECRUITING
Registry status
NA
Development phase
101 participants
Enrollment target
7
Study locations

Study Summary

A prospective, open-label, single arm interventional trial evaluating the safety and performance of the in-clinic and extended monitoring of the lower urinary tract using the Glean Urodynamics System.

Interventions

  • DEVICE Glean Urodynamics System

Study Locations (7)

Maryland

  • Chesapeake Urology Associates - Hanover
  • Chesapeake Urology Associates - Owings Mills

Missouri

  • Urology of St. Louis - St Louis

Ohio

  • MetroHealth - Cleveland

South Carolina

  • Southern Urogynecology Wellness & Aesthetics - West Columbia

South Dakota

  • Sanford Health - Sioux Falls

Texas

  • Urology Partner of North Texas - Arlington

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2026-02
Est. Completion 2027-06
Phase NA

Sponsor

Bright Uro

5 total trials

What the Registry Record Tells You About NCT07425015

The ClinicalTrials.gov registry entry for NCT07425015 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 549-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (82% lower). The listed sponsor is Bright Uro, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Glean Urodynamics System is the first listed.

NCT07425015 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Maryland, Missouri, Ohio.

Frequently Asked Questions

What is clinical trial NCT07425015 about?

NCT07425015 is a clinical study titled "Ambulatory Long Length URodynamics Evaluation". A prospective, open-label, single arm interventional trial evaluating the safety and performance of the in-clinic and extended monitoring of the lower urinary tract using the Glean Urodynamics System.

What is the current status of trial NCT07425015?

This trial is currently recruiting. It is a NA study. The enrollment target is 101 participants. The study started on 2026-02. Estimated completion is 2027-06.

What conditions does trial NCT07425015 study?

This clinical trial studies the following conditions: Benign Prostatic Hyperplasia, Urinary Bladder, Overactive, Urology, Urodynamics, Urinary Incontinence (UI).

What interventions are being tested in trial NCT07425015?

The interventions under investigation include: Glean Urodynamics System (DEVICE).

Who is sponsoring clinical trial NCT07425015?

This trial is sponsored by Bright Uro, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07425015 being conducted?

This trial has 7 study locations across Maryland, Missouri, Ohio, South Carolina, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Benign Prostatic Hyperplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.